IL-4 levels are significantly higher in patients treated with dupilumab compared to AD patients without dupilumab (p<0.05); when comparing IL-4 levels to the control group, there wasn’t found significant difference in patients without dupilumab; in patients with dupilumab the difference wasn’t found statistically significant also, but the p-value is on borderline of significance (p-value=0.0584). The gene discussed is IL4; the disease is Alzheimer disease.